0001104659-21-008179.txt : 20210127
0001104659-21-008179.hdr.sgml : 20210127
20210127161718
ACCESSION NUMBER: 0001104659-21-008179
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210125
FILED AS OF DATE: 20210127
DATE AS OF CHANGE: 20210127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pellizzari Christine A
CENTRAL INDEX KEY: 0001127430
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30739
FILM NUMBER: 21559940
MAIL ADDRESS:
STREET 1: 10 FINDERNE AVENUE
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER NAME:
FORMER CONFORMED NAME: PELLIZZARI CHRISTINE A
DATE OF NAME CHANGE: 20001030
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INSMED Inc
CENTRAL INDEX KEY: 0001104506
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 541972729
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 US HIGHWAY 202/206
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
BUSINESS PHONE: 908-977-9900
MAIL ADDRESS:
STREET 1: 700 US HIGHWAY 202/206
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: INSMED INC
DATE OF NAME CHANGE: 20000128
4
1
tm213966-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-01-25
0
0001104506
INSMED Inc
INSM
0001127430
Pellizzari Christine A
700 US HIGHWAY 202/206
BRIDGEWATER
NJ
08807
0
1
0
0
Chief Legal Officer
Common Stock
2021-01-25
4
M
0
15000
10.85
A
155721
D
Common Stock
2021-01-25
4
S
0
15000
42.95
D
140721
D
Common Stock
2021-01-25
4
M
0
6000
10.85
A
146721
D
Common Stock
2021-01-25
4
S
0
6000
43.84
D
140721
D
Common Stock
2021-01-26
4
M
0
2600
10.85
A
143321
D
Common Stock
2021-01-26
4
S
0
2600
44.04
D
140721
D
Stock Option (right to buy)
10.85
2021-01-25
4
M
0
15000
0
D
2026-05-19
Common Stock
15000
30150
D
Stock Option (right to buy)
10.85
2021-01-25
4
M
0
6000
0
D
2026-05-19
Common Stock
6000
24150
D
Stock Option (right to buy)
10.85
2021-01-26
4
M
0
2600
0
D
2026-05-19
Common Stock
2600
21550
D
The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
This is the weighted average sales price representing 15,000 shares sold at prices ranging from $42.75 to $43.58 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 6,000 shares sold at prices ranging from $43.75 to $43.94 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 2,600 shares sold at prices ranging from $43.75 to $44.23 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request
The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant.
/s/ Christine Pellizzari
2021-01-27